Navigation Links
Access Pharmaceuticals Announces $2.7 Million New Equity
Date:1/29/2008

, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-KSB and other reports
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Clinical and Economical Considerations For IV Push Drug Delivery by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Professional Use
2. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
3. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
4. Access Pharmaceuticals Announces $19.5 Million Recapitalization
5. Access Genetics Announces New Executive Appointments
6. Pharmasset Accesses up to $30 Million of Working Capital
7. Monitorforhire.com Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors
8. CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care
9. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
10. Access Highlighted in Recent BusinessWeek Article
11. Concuity Announces the Launch of Its New Fully Accessible Website - Concuity.Com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Decision Resources Group finds ... directors in the United States ... market penetration will be the level of savings ... the expected lower cost to patients. Payers plan ... meet their pricing expectations in order to encourage ...
(Date:7/30/2014)...  Replikins Ltd. today released new data on changes ... the current outbreaks, the mean Ebola Reston gene Replikin ... 1995 and 2002 was 1.1; the mean Replikin Count ... in 2013, thus predicting the current outbreaks in humans. ... shown to be able to predict outbreaks (1).  For ...
(Date:7/30/2014)... Sales Horizons, a leader in sales training ... programs for companies engaged in complex B2B sales. , ... of salespeople over 25 years in market-leading Fortune 500 ... customized to address the unique sales challenges of companies ... program consists of two parts: Mastering the Complex ...
(Date:7/30/2014)... 30, 2014 July 30, 2014. ... biotechnology firm that provides DNA-based authentication and security solutions ... Vice President of Life Sciences, a newly created position, ... Dr. Hogan will lead APDN’s drive to build its ... biotech and healthcare customers, provide guidance to APDN’s R&D ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... 26 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today ... the addition of two new members. Appointed to the company,s ... Chatfield. With their addition, the company board now has eight ... of the U. S. Selective Service System from November of ...
... Pa., Oct. 26 Cadient Group , ... today announced that it has been recognized as one of ... the Greater Philadelphia region for the second consecutive year. ... during the five year period from 2004-2008. Cadient Group ...
... , ... blue dye test alternative using innovative laser technology has been installed at ... processes. Bayer China has acquired Sepha ’s ‘BlisterScan’ machines for non-destructive leak testing ... ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Expands Board of Directors 2Cadient Group Ranks as Deloitte Fast 50 Company for Greater Philadelphia Region for Second Consecutive Year 2Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process 2Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process 3
(Date:7/30/2014)... about what they eat, the Food and Drug Administration ... Nutrition Facts label found on nearly every food product ... Engineering News (C&EN), the weekly news magazine of ... and the fight that has ensued. , Britt Erickson, ... the Nutrition Facts label has remained largely the same ...
(Date:7/30/2014)... major interest in neuroscience. A large number of ... of Wallerian degeneration: transcription factor activation, immune response, ... responses in the distal segment of the sciatic ... in gene expression between the proximal and distal ... from Nantong University, China used microarrays to analyze ...
(Date:7/30/2014)... Calif. , July 30, 2014 ... with the United States Air Force Research Laboratory ... by Binghamton University to ... performance monitoring (HPM). The $425,000 project, with contributions ... packaging firm i3 Electronics, Inc. ( Endicott, ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... Nature Genetics, is based on data from more than ... but also discovered ten new genes. Altogether they explain ... The analysis produced some biologically insightful findings. Several ... let-7, which affects the regulation of other genes. This ...
... University of Leicester engineer has won a share of ... cancer. In an unusual move, Dr. Declan Bates, ... the University of Leicester, is co-recipient of 1,068,000 in ... the Engineering and Physical Sciences Research Council (EPSRC) and ...
... to determine if global warming threatens the polar bear population ... listing the polar bear as an endangered species, according to ... journal of the Institute for Operations Research and the Management ... ordered the Interior Department to decide by May 15 whether ...
Cached Biology News:How body size is regulated 2Engineer to spearhead research into cell metabolism and medical injuries 2Federal polar bear research critically flawed, says study in INFORMS journal 2
... controller is the successor to the original DS-U1. ... of the cameras in the Nikon DS camera ... interface. The DS-U2 transmits information at high speed, ... both hub and mass storage USB 2.0 interfaces. ...
...
... Liquid. 100 ml supplied as a ... remove antibodies from membrane-bound proteins without ... stripping chemiluminescent or radioisotopic signals from ... Western blots. Supplied as a 5X ...
... The 500 optimization kit is for ... of interest. The kit is recommended when ... biolistic system. The kit includes 0.25 g ... 1.6 micrometer diameter gold microcarriers, 100 each ...
Biology Products: